Actively Recruiting
TTVR STRONG Under Coverage With Evidence Development (CED) Study
Led by Edwards Lifesciences · Updated on 2025-03-28
2044
Participants Needed
1
Research Sites
406 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This Coverage with Evidence Development (CED) study measures the long-term health outcomes of patients with severe, symptomatic Tricuspid Regurgitation who received a Transcatheter Tricuspid Valve Replacement procedure using the EVOQUE system.
CONDITIONS
Official Title
TTVR STRONG Under Coverage With Evidence Development (CED) Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Medicare eligible patients who have received an EVOQUE device or are EVOQUE eligible
- Patients must have at least severe Tricuspid Regurgitation
You will not qualify if you...
- Commercially insured patients who have received an EVOQUE device or are EVOQUE eligible
- Medicare eligible patients with less than severe Tricuspid Regurgitation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Edwards Lifesciences
Irvine, California, United States, 92614
Actively Recruiting
Research Team
T
TMTT GHER
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here